|
|
|
09.04.25 - 18:03
|
IMPLANET Reports Revenue of €2.58 Million in Q1 2025, Up +16% (Business Wire)
|
|
|
+16% revenue growth compared to Q1 2024
Performance driven by strong export growth outside France and the United States (+42% vs. Q1 2024)
BORDEAUX, France & BOSTON--(BUSINESS WIRE)--Regulatory News:
IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME), a medical technology company specialized in implants for orthopedic surgery and the distribution of advanced medical equipment, today announced its revenue for the first quarter of 2025.
Ludovic Lastennet, IMPLANET's Chief Executive Officer, stated: “We continue on our growth trajectory with a 16% increase in revenue in the first quarter of 2025. This momentum is driven by the sustained development of our international activities, following agreements signed at the end of 2024—particularly in markets outside France and the United States, which saw a 42% increase. The sharp rise in our medical equipment distribution business confirms the relevance of our strategy and the potential of our partnership with Sanyou Medical. Buoyed by these...
|
|
|
04.03.25 - 18:06
|
IMPLANET Reports Its 2024 Full-Year Results (Business Wire)
|
|
|
2024 full-year revenue up +26% compared to fiscal year 2023
Continued strict control of operational costs throughout the period
BORDEAUX, France & BOSTON--(BUSINESS WIRE)--Regulatory News:
IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME), a medical technology company specialized in implants for orthopedic surgery and the distribution of advanced medical equipment, today announced its results for the fiscal year ended December 31, 2024, as approved by the Board of Directors on March 4, 2025.
Ludovic Lastennet, IMPLANET's Chief Executive Officer, stated: “Throughout 2024, we successfully balanced the revitalization of our commercial activity with strict resource management. The benefits of this strategy are reflected in today's results, with strong full-year revenue growth combined with a significant reduction in our operating loss over the year. The investments and commercial launches we executed during the period, particularly in the United States, translated into highly satisfact...
|
|
|
14.01.25 - 18:06
|
IMPLANET Announces 2024 Full-Year Revenue Up 26% to €9.4 Million (Business Wire)
|
|
|
Continued acceleration in quarterly revenue growth since Q2 2024, with Q4 2024 reaching nearly €3.0 million, up 81% versus 2023
Strong full-year performance in the medical equipment distribution business, generating €2.3 million in revenue
BORDEAUX, France & BOSTON--(BUSINESS WIRE)--Regulatory News:
IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans), a medical technology company specializing in implants for orthopedic surgery and the distribution of technological medical equipment, today announces its full-year 2024 revenue and cash position as of December 31, 2024.
Ludovic Lastennet, IMPLANET's Chief Executive Officer, stated: “The strong commercial performance achieved in the second half of 2024, with 66% growth compared to the same period last year, underscores the effectiveness of the development model implemented at the start of 2024. Building on our expertise in spine surgery and the synergy between our product ranges, the combination of implant sales w...
|
|
|
06.01.25 - 18:06
|
IMPLANET Announces Its 2025 Financial Calendar (Business Wire)
|
|
|
BORDEAUX, France & BOSTON--(BUSINESS WIRE)--Regulatory News:
IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans), a medical technology company specializing in implants for orthopedic surgery and the distribution of technological medical equipment, today announces its schedule for the publication of financial information for 2025.
Events
Dates*
2024 Full-Year Revenue
January 14, 2025
2024 Full-Year Results
March 4, 2025
Annual General Meeting
March 28, 2025
2025 First-Quarter Revenue
April 9, 2025
2025 First-Half Revenue
July 8, 2025
2025 First-Half Results
September 16, 2025
2025 Third-Quarter Revenue
October 7, 2025
(*) Subject to change. Press releases will be issued after market close.
Upcoming financial publication
2024 Full-Year Revenue, on January 14, 2025 after market
About IMPLANET
Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery and distributing medical technology equipment. Its activity...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
